Health Partners
A part of Jefferson Health Plans

HEALTH PARTNERS PLANS
2024 PRIOR AUTHORIZATION REQUEST FORM

Apomorphine (Non-PDL)

Phone: 215-991-4300 **Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:	
HPP HPP Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Patient Primary Phone:	NPI:	*PA PROMISe ID:*
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Line of Business: ☐ Medicaid ☐ CHIP	*Specialty Pharmacy (if applicable):*	
Drug Name:	**Strength:**	
Quantity:	**Refills:**	
Directions:		
Diagnosis Code:	**Diagnosis:**	

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.
Please answer the following questions and sign.

Q1. Is this a renewal request? If yes, go to 2. If not, go to 6.

☐ Yes ☐ No

Q2. Does the patient continue to need Apomorphine and meet the criteria identified for initial approval?

☐ Yes ☐ No

Q3. Does the patient tolerate the medication without significant or serious side effects (must attach documentation)?

☐ Yes ☐ No

Q4. Has the patient had an improvement in symptoms from baseline (must attach documentation)?

☐ Yes ☐ No

Q5. Is there documentation of a treatment plan including duration of treatment (must attach documentation)?

☐ Yes ☐ No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners
A part of Jefferson Health Plans

HEALTH PARTNERS PLANS
2024 PRIOR AUTHORIZATION REQUEST FORM

Apomorphine (Non-PDL)

Phone: 215-991-4300 **Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:

Q6. Does the patient have a diagnosis of advance Parkinson's Disease (PD) with documented hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) (documentation must be attached)?

☐ Yes ☐ No

Q7. Is the medication being prescribed by or in consultation with a specialist (who specializes in the treatment of PD or a neurologist)?

☐ Yes ☐ No

Q8. Does the patient have a history of therapeutic failure, a contraindication to or intolerance of the preferred Antiparkinson's agents (such as carbidopa-levodopa, pramipexole, ropinirole, bromocriptine, amantadine, selegiline, trihexyphenidyl, benztropine,) (Must attach documentation)?

☐ Yes ☐ No

Q9. Will the initial “test” dose be given under medical supervision?

☐ Yes ☐ No

Q10. Will the medication ONLY be given via subcutaneous route of administration?

☐ Yes ☐ No

Q11. Will trimethobenzamide be started 3 days prior to the initial dose of Apomorphine, and continue as long as necessary to control nausea and vomiting (generally no longer than 2 months)?

☐ Yes ☐ No

Q12. Will this medicine be administered with 5HT3 antagonists (such as ondansetron) to control nausea?

☐ Yes ☐ No

Q13. Has renal function been evaluated and has medication been dose adjusted for renal impairment, if necessary?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners
A part of Jefferson Health Plans

HEALTH PARTNERS PLANS
2024 PRIOR AUTHORIZATION REQUEST FORM

Apomorphine (Non-PDL)

Phone: 215-991-4300 **Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:

☐ Yes	☐ No
Q14. Has a cardiac evaluation been performed (including assessment of QTc interval)?	
☐ Yes	☐ No
Q15. Has the patient been counseled on the risks of using alcohol, antihypertensive medications, and vasodilating medications while taking this medication	
☐ Yes	☐ No
Q16. Will the patient abstain from alcohol while taking this medicine?	
☐ Yes	☐ No
Q17. Is the treatment plan attached showing how the medication will be administered, duration of therapy, and other medications that will be continued?	
☐ Yes	☐ No
Q18. Is each dose less than or equal to 0.6 mL with a dosing frequency of less than or equal to five times per day?	
☐ Yes	☐ No
Q19. Additional Information:	

Prescriber Signature

Date

Updated for 2024

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document